Literature DB >> 18474371

Elevated serum inflammatory markers in post-poliomyelitis syndrome.

Christopher B Fordyce1, Donald Gagne, Farzaneh Jalili, Sudabeh Alatab, Douglas L Arnold, Deborah Da Costa, Stefan Sawoszczuk, Caroline Bodner, Stan Shapiro, Jean-Paul Collet, Ann Robinson, Jean-Pierre Le Cruguel, Yves Lapierre, Amit Bar-Or, Daria A Trojan.   

Abstract

OBJECTIVES: To determine (i) whether serum inflammatory markers TNFalpha, IL-1beta. IL-6, and leptin are increased in post-poliomyelitis syndrome (PPS) compared to healthy controls; and (ii) whether an association exists between elevated inflammatory markers and clinical parameters in PPS. The cause of PPS is unknown, but abnormal inflammatory responses have been implicated in several small studies.
METHODS: Serum inflammatory markers were measured (by Luminex) in 51 PPS patients and 26 normal controls. Clinical parameters assessed included disease duration, muscle strength (Medical Research Council sumscore), fatigue (Fatigue Severity Scale and Multidimensional Fatigue Inventory), and pain (visual analog scale scores).
RESULTS: In PPS, TNFalpha levels, as well as IL-6 and leptin were significantly increased compared to controls (Wilcoxon rank-sum test, p=0.03 for TNFalpha, p=0.03 for IL-6, p=0.01 for leptin). The elevated TNFalpha levels in PPS were associated with increased pain due to illness (Spearman correlation coefficient r=0.36, 95% C.I. 0.09 to 0.57) and specifically, with muscle pain (r=0.38, 95% C.I. 0.11 to 0.59). There were no correlations between inflammatory markers in PPS and joint pain, muscle strength, fatigue, or disease duration.
CONCLUSIONS: Serum TNFalpha, IL-6 and leptin levels are abnormally increased in PPS patients. Elevated TNFalpha levels appear to be specifically associated with increased muscle pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474371     DOI: 10.1016/j.jns.2008.03.015

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  IVIG treatment in post-polio patients: evaluation of responders.

Authors:  Gunilla Ostlund; Lisbet Broman; Lars Werhagen; Kristian Borg
Journal:  J Neurol       Date:  2012-05-17       Impact factor: 4.849

2.  A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis.

Authors:  J M Burton; S Kimball; R Vieth; A Bar-Or; H-M Dosch; R Cheung; D Gagne; C D'Souza; M Ursell; P O'Connor
Journal:  Neurology       Date:  2010-04-28       Impact factor: 9.910

3.  Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis.

Authors:  Samantha Kimball; Reinhold Vieth; Hans-Michael Dosch; Amit Bar-Or; Roy Cheung; Donald Gagne; Paul O'Connor; Cheryl D'Souza; Melanie Ursell; Jodie M Burton
Journal:  J Clin Endocrinol Metab       Date:  2011-06-22       Impact factor: 5.958

4.  Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease.

Authors:  André Charlett; R John Dobbs; Sylvia M Dobbs; Clive Weller; Mohammad A A Ibrahim; Tracy Dew; Roy Sherwood; Norman L Oxlade; J Malcolm Plant; James Bowthorpe; Andrew J Lawson; Alan Curry; Dale W Peterson; Ingvar T Bjarnason
Journal:  Gut Pathog       Date:  2009-11-26       Impact factor: 4.181

5.  Update on current and emerging treatment options for post-polio syndrome.

Authors:  Elisabeth Farbu
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

6.  Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up.

Authors:  Henrik Gonzalez; Mohsen Khademi; Kristian Borg; Tomas Olsson
Journal:  J Neuroinflammation       Date:  2012-07-09       Impact factor: 8.322

7.  Elevated blood lipids are uncommon in patients with post-polio syndrome--a cross sectional study.

Authors:  Eva Melin; Thomas Kahan; Kristian Borg
Journal:  BMC Neurol       Date:  2015-04-29       Impact factor: 2.474

Review 8.  Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis.

Authors:  Yao-Hsien Huang; Hung-Chou Chen; Kuang-Wei Huang; Po-Chih Chen; Chaur-Jong Hu; Chin-Piao Tsai; Ka-Wai Tam; Yi-Chun Kuan
Journal:  BMC Neurol       Date:  2015-03-22       Impact factor: 2.474

9.  Circadian fatigue or unrecognized restless legs syndrome? The post-polio syndrome model.

Authors:  Andrea Romigi; Michelangelo Maestri
Journal:  Front Neurol       Date:  2014-07-07       Impact factor: 4.003

10.  Normal serum levels of immune complexes in postpolio patients.

Authors:  Eva Melin; Azita Sohrabian; Johan Rönnelid; Kristian Borg
Journal:  Results Immunol       Date:  2014-06-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.